Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)

BACKGROUND: We hypothesized that the high-dose opioid requirement in patients carrying the rs4680-GG variant in the COMT gene encoding catechol-O-methyltransferase would be greater for patients taking morphine than for those taking oxycodone, thus providing a much-needed biomarker to inform opioid s...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuoka, Hiromichi, Tsurutani, Junji, Chiba, Yasutaka, Fujita, Yoshihiko, Sakai, Kiyohiro, Yoshida, Takeshi, Nakura, Miki, Sakamoto, Ryo, Makimura, Chihiro, Ohtake, Yoichi, Tanaka, Kaoru, Hayashi, Hidetoshi, Takeda, Masayuki, Okuno, Tatsuya, Takegawa, Naoki, Haratani, Koji, Koyama, Atsuko, Nishio, Kazuto, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020805/
https://www.ncbi.nlm.nih.gov/pubmed/36426809
http://dx.doi.org/10.1093/oncolo/oyac233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020805/
https://www.ncbi.nlm.nih.gov/pubmed/36426809
http://dx.doi.org/10.1093/oncolo/oyac233

Ejemplares similares